Improved Gross Profit Margins
Gross profit margin for Q3 2025 was 42.4%, an increase from 39.3% in Q3 2024.
Contract Manufacturing Growth
Contract manufacturing revenue totaled $907,000 in Q3 2025, showing slight year-over-year and sequential growth. Strong partnerships, such as with Cintas, continue to drive performance.
Strategic Partnerships
NEXGEL signed an agreement with iRhythm to supply hydrogels for their Zio ECG heart monitoring system, with anticipated orders in Q4 2025.
Product Expansion and Market Approvals
New product launches in consumer segments, including expanded beauty lines and new skin care solutions. Also, Metagel received approval from Health Canada to sell SilverSeal.
Non-Dilutive Financing
Received $1 million from Stada to support product launches and marketing, strengthening the financial position.